Aclaris Therapeutics (ACRS) Stock: Why It's Up Today
Updated Oct 19, 2026, 12:05 PM ET · intraday price
- Trading at $3.36 as of 12:05 PM ET, +2.44% vs the prior close of $3.28.
- Volume 536.15K shares, 0.2x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ACRS rises 2.4% to $3.36. Trading at $3.36 (intraday, 12:05 PM ET), +2.44% vs the prior close of $3.28. Day range $3.26–$3.38, opened at $3.28.
ACRS daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — ACRS rises 2.4% to $3.36
- Trading at $3.36 (intraday, 12:05 PM ET), +2.44% vs the prior close of $3.28. Day range $3.26–$3.38, opened at $3.28.
- Volume was 536.15K shares, 0.2x its 50-day average of 2.87M — lighter than usual.
- Price is -36.3% vs its 50-day average ($5.27) and -25.0% vs its 200-day average ($4.48).
- 52-week range $1.88–$6.60; the current price sits at 31% of that range, 49.1% below the 52-week high.
Oct 16, 2026 — ACRS slides 6.0% to $3.28, a 6-month low
- Closed at $3.28, -6.02% vs the prior close of $3.49. Day range $3.24–$3.53, opened at $3.51.
- Volume was 2.46M shares, 0.9x its 50-day average of 2.88M.
- Price is -38.4% vs its 50-day average ($5.32) and -26.8% vs its 200-day average ($4.48).
- 52-week range $1.88–$6.60; today's close sits at 30% of that range, 50.3% below the 52-week high.
Oct 15, 2026 — ACRS jumps 3.3% to $3.49
- Closed at $3.49, +3.25% vs the prior close of $3.38. Day range $3.34–$3.51, opened at $3.42.
- Volume was 2.59M shares, 0.9x its 50-day average of 2.94M.
- Price is -35.1% vs its 50-day average ($5.38) and -22.0% vs its 200-day average ($4.48).
- 52-week range $1.83–$6.60; today's close sits at 35% of that range, 47.1% below the 52-week high.
Oct 14, 2026 — ACRS dips 2.6% to $3.38, a 6-month low, 3 down days in a row
- Closed at $3.38, -2.59% vs the prior close of $3.47. Day range $3.34–$3.47, opened at $3.38.
- Volume was 2.59M shares, 0.9x its 50-day average of 2.94M.
- Price is -37.8% vs its 50-day average ($5.44) and -24.5% vs its 200-day average ($4.47).
- 52-week range $1.74–$6.60; today's close sits at 34% of that range, 48.8% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ACRS slides 3.6% to $3.47
- Closed at $3.47, -3.61% vs the prior close of $3.60. Day range $3.41–$3.65, opened at $3.65.
- Volume was 3.44M shares, 1.2x its 50-day average of 2.91M.
- Price is -36.8% vs its 50-day average ($5.49) and -22.4% vs its 200-day average ($4.47).
- 52-week range $1.74–$6.60; today's close sits at 36% of that range, 47.4% below the 52-week high.
Oct 12, 2026 — ACRS slides 6.0% to $3.60
- Closed at $3.60, -6.01% vs the prior close of $3.83. Day range $3.59–$3.84, opened at $3.80.
- Volume was 3.43M shares, 1.2x its 50-day average of 2.87M.
- Price is -34.9% vs its 50-day average ($5.53) and -19.5% vs its 200-day average ($4.47).
- 52-week range $1.74–$6.60; today's close sits at 38% of that range, 45.5% below the 52-week high.
Oct 9, 2026 — ACRS rises 1.1% to $3.83 on 1.8x normal volume
- Closed at $3.83, +1.06% vs the prior close of $3.79. Day range $3.64–$3.94, opened at $3.76.
- Volume was 5.06M shares, 1.8x its 50-day average of 2.81M — unusually heavy trading.
- Price is -31.1% vs its 50-day average ($5.56) and -14.3% vs its 200-day average ($4.47).
- 52-week range $1.74–$6.60; today's close sits at 43% of that range, 42.0% below the 52-week high.
Oct 8, 2026 — ACRS jumps 11.5% to $3.79 on 3.3x normal volume
- Closed at $3.79, +11.47% vs the prior close of $3.40. Day range $3.18–$3.82, opened at $3.37.
- Volume was 8.74M shares, 3.3x its 50-day average of 2.66M — unusually heavy trading.
- Price is -32.2% vs its 50-day average ($5.59) and -15.1% vs its 200-day average ($4.46).
- 52-week range $1.74–$6.60; today's close sits at 42% of that range, 42.6% below the 52-week high.
Oct 7, 2026 — ACRS slides 8.1% to $3.40, a 6-month low on 3.6x normal volume
- Closed at $3.40, -8.11% vs the prior close of $3.70. Day range $3.32–$3.62, opened at $3.60.
- Volume was 9.00M shares, 3.6x its 50-day average of 2.51M — unusually heavy trading.
- Price is -39.5% vs its 50-day average ($5.62) and -23.8% vs its 200-day average ($4.46).
- 52-week range $1.74–$6.60; today's close sits at 34% of that range, 48.5% below the 52-week high.
- That makes 7 straight losses.
Oct 6, 2026 — ACRS slides 13.3% to $3.70, a 6-month low, 6 down days in a row
- Closed at $3.70, -13.35% vs the prior close of $4.27. Day range $3.65–$4.24, opened at $4.22.
- Volume was 3.53M shares, 1.4x its 50-day average of 2.54M.
- Price is -34.6% vs its 50-day average ($5.66) and -17.0% vs its 200-day average ($4.46).
- 52-week range $1.74–$6.60; today's close sits at 40% of that range, 43.9% below the 52-week high.
- That makes 6 straight losses.
Oct 5, 2026 — ACRS dips 2.7% to $4.27, a 3-month low on 2.9x normal volume
- Closed at $4.27, -2.73% vs the prior close of $4.39. Day range $4.07–$4.41, opened at $4.34.
- Volume was 7.02M shares, 2.9x its 50-day average of 2.41M — unusually heavy trading.
- Price is -24.9% vs its 50-day average ($5.69) and -4.1% vs its 200-day average ($4.45).
- 52-week range $1.74–$6.60; today's close sits at 52% of that range, 35.3% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — ACRS dips 0.5% to $4.39, a 3-month low on 2.7x normal volume
- Closed at $4.39, -0.45% vs the prior close of $4.41. Day range $4.20–$4.52, opened at $4.44.
- Volume was 6.21M shares, 2.7x its 50-day average of 2.31M — unusually heavy trading.
- Price is -23.1% vs its 50-day average ($5.71) and -1.3% vs its 200-day average ($4.45).
- 52-week range $1.74–$6.60; today's close sits at 55% of that range, 33.5% below the 52-week high.
- That makes 4 straight losses.
ACRS bull case vs bear case (from the data)
- No clear positive signal in the price trend, filings or insider data right now.
- Price is -36.3% vs its 50-day average — short-term trend is down.
- Price is -25.0% vs its 200-day average — below the long-term trend line.
- Annual revenue fell 58.2% in the latest fiscal year (SEC XBRL).
- Latest fiscal-year net income: loss of $64.92M.
- Insider selling outweighs buying: 4 sales vs 0 open-market buys among the 4 most recent reported insider trades (Form 4, last 12 months).
- Share count up 35.9% in a year (dilution).
- High volatility: average daily move of 5.2% over 20 sessions.
ACRS latest news & SEC filings
Every SEC filing by or about ACRS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 21, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Aug 6, 2026 · Form S-3ASR — S-3ASR filing
S-3ASR filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $1.63M (prior year $1.78M) (-8.3% vs Jun 30, 2025)
- Net income: -$21.50M (prior year -$15.43M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.15 (prior year -$0.13) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade ACRS
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.16% (largest 16.2%). That is a volatile stock.
- Liquidity: about 3.77M shares (≈$12.65M) trade per day on average.
- 52-week position: $3.36 vs a range of $1.88–$6.60 (31% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 4 sales; latest: Braden Michael Leonard sold 300,000 shares on Apr 23, 2026.
- Latest filings: 8-K Aug 6, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 147.20M shares outstanding (Jul 31, 2026), +35.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ACRS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 3.28 | 3.38 | 3.26 | 3.36 | 536.15K |
| Oct 16, 2026 | 3.51 | 3.53 | 3.24 | 3.28 | 2.46M |
| Oct 15, 2026 | 3.42 | 3.51 | 3.34 | 3.49 | 2.59M |
| Oct 14, 2026 | 3.38 | 3.47 | 3.34 | 3.38 | 2.59M |
| Oct 13, 2026 | 3.65 | 3.65 | 3.41 | 3.47 | 3.44M |
| Oct 12, 2026 | 3.80 | 3.84 | 3.59 | 3.60 | 3.43M |
| Oct 9, 2026 | 3.76 | 3.94 | 3.64 | 3.83 | 5.06M |
| Oct 8, 2026 | 3.37 | 3.82 | 3.18 | 3.79 | 8.74M |
| Oct 7, 2026 | 3.60 | 3.62 | 3.32 | 3.40 | 9.00M |
| Oct 6, 2026 | 4.22 | 4.24 | 3.65 | 3.70 | 3.53M |
| Oct 5, 2026 | 4.34 | 4.41 | 4.07 | 4.27 | 7.02M |
| Oct 2, 2026 | 4.44 | 4.52 | 4.20 | 4.39 | 6.21M |
| Oct 1, 2026 | 5.18 | 5.18 | 4.35 | 4.41 | 5.17M |
| Sep 30, 2026 | 5.30 | 5.39 | 5.21 | 5.26 | 2.26M |
| Sep 29, 2026 | 5.42 | 5.45 | 5.16 | 5.28 | 2.05M |
| Sep 28, 2026 | 5.07 | 5.47 | 5.02 | 5.43 | 2.43M |
| Sep 25, 2026 | 5.39 | 5.54 | 5.09 | 5.15 | 1.47M |
| Sep 24, 2026 | 5.24 | 5.44 | 5.14 | 5.38 | 2.49M |
| Sep 23, 2026 | 5.70 | 5.74 | 5.03 | 5.26 | 1.96M |
| Sep 22, 2026 | 5.63 | 5.76 | 5.50 | 5.72 | 2.88M |
About Aclaris Therapeutics
Aclaris Therapeutics (ACRS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WAYNE, PA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1557746.
ACRS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Hugh M. Davis | President and COO | Feb 6, 2026 |
| Maxine Gowen | Director | Jun 8, 2026 |
| William D. Humphries | Director | Jun 8, 2026 |
| Vincent Milano | Director | Jun 8, 2026 |
| Anand Mehra | Director | Jun 8, 2026 |
| Christopher P. Molineaux | Director | Jun 8, 2026 |
| Andrew N Schiff | Director | Jun 8, 2026 |
| Neal Walker | CEO | Feb 6, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Kevin Balthaser | Chief Financial Officer | Mar 3, 2026 |
| Hugh M. Davis | President and COO | Feb 6, 2026 |
| Jesse Wayne Hall | Chief Medical Officer | May 5, 2026 |
| Roland Wilhelm Kolbeck | Chief Scientific Officer | Aug 4, 2026 |
| James Loerop | Chief Business Officer | Feb 6, 2026 |
| Neal Walker | CEO | Feb 6, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Apr 23, 2026 | Braden Michael Leonard | Sale | 300,000 | $4.53 |
| Apr 23, 2026 | Braden Michael Leonard | Sale | 300,000 | $4.53 |
| Apr 23, 2026 | Braden Michael Leonard | Sale | 300,000 | $4.53 |
| Apr 23, 2026 | Braden Michael Leonard | Sale | 300,000 | $4.53 |
ACRS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $7.83M | $-64.92M | -0.53 | $-47.11M |
| Dec 31, 2024 | $18.72M | $-132.06M | -1.71 | $-20.07M |
| Dec 31, 2023 | $31.25M | $-88.48M | -1.27 | $-78.33M |
| Dec 31, 2022 | $29.75M | $-86.91M | -1.33 | $-67.57M |
| Dec 31, 2021 | $6.76M | $-90.86M | -1.60 | $-52.13M |
Latest balance sheet: total assets $179.69M, total liabilities $55.11M, cash $19.17M (as of Jun 30, 2026).
ACRS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $6.09 |
| May 7, 2026 | 8-K Item 2.02 (results) | $4.86 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $3.13 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $2.27 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $1.57 |
| May 8, 2025 | 8-K Item 2.02 (results) | $1.31 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $1.95 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $2.26 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Feb 27, 2024 | 8-K Item 2.02 (results) | — |
| Jan 19, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on ACRS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: intraday data as of Oct 19, 2026, 12:05 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.